Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Per Lindnér"'
Autor:
Lillian Streichart, Marie Felldin, Jana Ekberg, Lars Mjörnstedt, Per Lindnér, Annette Lennerling, Verena Bröcker, Johan Mölne, Jan Holgersson, Kristien Daenen, Lars Wennberg, Tomas Lorant, Seema Baid-Agrawal
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-15 (2024)
Abstract Background Chronic active antibody-mediated rejection (caAMR) in kidney transplants is associated with irreversible tissue damage and a leading cause of graft loss in the long-term. However, the treatment for caAMR remains a challenge to dat
Externí odkaz:
https://doaj.org/article/44ba75643e6d4314bde9aee06803a006
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-13 (2022)
Abstract Background Around one fourth of patients with colorectal cancer present themselves with distant metastases at the time of diagnosis, and one additional one fifth of the patients will develop distant metastases during the disease, most common
Externí odkaz:
https://doaj.org/article/0e163e3ee6d64965ba40e3e175a3082f
Autor:
Jana Ekberg, Seema Baid-Agrawal, Bente Jespersen, Ragnar Källén, Ehab Rafael, Karin Skov, Per Lindnér
Publikováno v:
Kidney International Reports, Vol 7, Iss 2, Pp 259-269 (2022)
Introduction: Steroid-based immunosuppression after transplantation increases the risk of post-transplant diabetes mellitus (PTDM), with adverse effects on patient and graft survival. In the SAILOR study, we investigated the safety and efficacy of co
Externí odkaz:
https://doaj.org/article/1073c313e6c24da3aabdc331dad89be5
Autor:
Amir Sedigh, MD, PhD, Torbjörn Lundgren, MD, PhD, Per Lindnér, MD, PhD, Johan Nordström, MD, Peetra Magnusson, MD, PhD, Janniz Jönsson, MD, Fredrik Carlsson, MD, PhD, Rutger Ploeg, MD, PhD, Tomas Lorant, MD, PhD
Publikováno v:
Transplantation Direct, Vol 9, Iss 1, p e1403 (2023)
Background. Pretreating porcine kidneys with Corline Heparin Conjugate (CHC) during hypothermic machine perfusion (HMP) has been shown to reduce preservation injury and improve early kidney function. In this first-in-human phase I study, the safety a
Externí odkaz:
https://doaj.org/article/e33b970ea67e4a7b8f59b8d0f9696af0
Autor:
Joakim Karlsson, Lisa M. Nilsson, Suman Mitra, Samuel Alsén, Ganesh Vilas Shelke, Vasu R. Sah, Elin M. V. Forsberg, Ulrika Stierner, Charlotta All-Eriksson, Berglind Einarsdottir, Henrik Jespersen, Lars Ny, Per Lindnér, Erik Larsson, Roger Olofsson Bagge, Jonas A. Nilsson
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
The genetics of uveal melanoma has mainly been studied in primary tumours. In this study, the authors perform whole genome sequencing as well as immune cell profiling of biopsy samples obtained from metastatic uveal melanoma patients, providing an up
Externí odkaz:
https://doaj.org/article/f71cb61f5c524059bea90c9e29676365
Autor:
Magnus Rizell, Fredrik Åberg, Mats Perman, Lars Ny, Liselotte Stén, Farida Hashimi, Joar Svanvik, Per Lindnér
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 1, Pp 478-484 (2020)
Combined hepatocellular-cholangiocarcinoma (CHC) is a rare type of primary liver cancer, speculated to arise from hepatic progenitor cells, and with a worse prognosis than hepatocellular carcinoma (HCC). Serum alpha-fetoprotein (AFP) levels may be on
Externí odkaz:
https://doaj.org/article/d032d9e3de154e35a122f16b8a0e9f8d
Autor:
Malin Sternby Eilard, Mats Andersson, Peter Naredi, Charalampos Geronymakis, Per Lindnér, Christian Cahlin, William Bennet, Magnus Rizell
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Patients with hepatocellular carcinoma waiting for liver transplantation are commonly treated with locoregional treatments, such as TACE and ablation, to prevent tumor progression and dropout and to improve long-term outcome after
Externí odkaz:
https://doaj.org/article/1acd4738c9574a138b181ef0afb9a457
Autor:
Junko Johansson, Roberta Kiffin, Ebru Aydin, Malin S. Nilsson, Kristoffer Hellstrand, Per Lindnér, Peter Naredi, Roger Olofsson Bagge, Anna Martner
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Hyperthermic isolated limb perfusion (ILP) with high-dose melphalan is a treatment option for melanoma patients with metastasis confined to limbs (in-transit metastasis). The therapy entails a complete response (CR) rate of 50–70%. Cellular immunit
Externí odkaz:
https://doaj.org/article/fb96808637124f1eb34048ff9f644c78
Autor:
Junko Johansson, Jan Siarov, Roberta Kiffin, Johan Mölne, Jan Mattsson, Peter Naredi, Roger Olofsson Bagge, Anna Martner, Per Lindnér
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Uveal melanoma is a malignant tumor of the eye that often metastasizes to the liver conferring poor prognosis. When comparing immune profiles in peripheral blood of untreated patients with uveal melanoma liver metastasis and healthy blood donors, it
Externí odkaz:
https://doaj.org/article/34d830837ad8404b9c5633195c833851
Autor:
Junko Johansson, Roberta Kiffin, Annica Andersson, Per Lindnér, Peter L. Naredi, Roger Olofsson Bagge, Anna Martner
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Hyperthermic isolated limb perfusion with melphalan (M-ILP) is a treatment option for melanoma patients with metastases confined to the limbs. This study aimed at defining the role of cellular immunity for the clinical response to M-ILP in melanoma p
Externí odkaz:
https://doaj.org/article/e9e4d6f981ec43e6ad58b39273204549